Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix(TM)

Stock Information for Axogen Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Axogen Inc.

Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®
Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference
Axogen, Inc Reports First Quarter 2024 Financial Results
Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.